Chris W. McAndrew
Partner
Christopher McAndrew is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati.
Prior to joining the firm, Chris was a postdoctoral fellow in Dr. Paul Goldsmith's laboratory at the National Institutes of Health in the National Cancer Institute, working under the Office of Science and Technology Partnerships division. In this role, he developed and evaluated next-generation antibody-based biomarker detection methods and systems for start-up biotech companies and in-house research; designed and purified antigens for antibody production in hosts; and screened antibodies for use in various methods and platforms. During his time at the National Institutes of Health, Chris also worked as an intern in the Office of Technology Transfer.
Previously, as a graduate student in the chemistry and biochemistry department at the University of California, San Diego, Chris studied the role of novel cyclin-like proteins in responses to DNA damage, as well as the crosstalk between the Fibroblast Growth Factor Receptor and the inflammatory response pathway. In addition, he worked as an intern at Tech Law performing patent and trademark due diligence.
Experience
Christopher McAndrew is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati.
Prior to joining the firm, Chris was a postdoctoral fellow in Dr. Paul Goldsmith's laboratory at the National Institutes of Health in the National Cancer Institute, working under the Office of Science and Technology Partnerships division. In this role, he developed and evaluated next-generation antibody-based biomarker detection methods and systems for start-up biotech companies and in-house research; designed and purified antigens for antibody production in hosts; and screened antibodies for use in various methods and platforms. During his time at the National Institutes of Health, Chris also worked as an intern in the Office of Technology Transfer.
Previously, as a graduate student in the chemistry and biochemistry department at the University of California, San Diego, Chris studied the role of novel cyclin-like proteins in responses to DNA damage, as well as the crosstalk between the Fibroblast Growth Factor Receptor and the inflammatory response pathway. In addition, he worked as an intern at Tech Law performing patent and trademark due diligence.
Education
- J.D., The George Washington University Law School, 2016
- Ph.D., Chemistry, University of California, San Diego, 2010Authored dissertation titled "Cell cycle and DNA damage response regulation by Spy1, and the intersection of FGFR and NFkappaB pathways"
- M.S., Chemistry, University of California, San Diego, 2007Participant, LEAN/Six Sigma Enterprise Certificate Program; Participant, FDA Regulatory Affairs Certificate Program; Recipient, Achievement Rewards for College Scientists Scholarship
- B.S., Biochemistry, University of Delaware, 2004Minors in Biological Sciences and Biomedical Engineering; Recipient, Howard Hughes Medical Institute Scholarship
Honors
- Recipient, Postdoctoral Training Grant, National Institutes of Health
- Recipient, Federal Technology Transfer Award, National Institutes of Health
Admissions
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., The George Washington University Law School, 2016
- Ph.D., Chemistry, University of California, San Diego, 2010Authored dissertation titled "Cell cycle and DNA damage response regulation by Spy1, and the intersection of FGFR and NFkappaB pathways"
- M.S., Chemistry, University of California, San Diego, 2007Participant, LEAN/Six Sigma Enterprise Certificate Program; Participant, FDA Regulatory Affairs Certificate Program; Recipient, Achievement Rewards for College Scientists Scholarship
- B.S., Biochemistry, University of Delaware, 2004Minors in Biological Sciences and Biomedical Engineering; Recipient, Howard Hughes Medical Institute Scholarship
Honors
- Recipient, Postdoctoral Training Grant, National Institutes of Health
- Recipient, Federal Technology Transfer Award, National Institutes of Health
Admissions
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
Select Publications
- Co-author with D. Hoffmeister, V. Norviel, P. Girinath, and C. Andres, "FDA Developments in 2015 and What's to Come in 2016," Law360, January 11, 2016
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with V. Norviel, E. Kepplinger, J. Chambers, and L. Lieto, "Strategies for Maximizing Patent Claim Scope and Patent Prosecution for Diagnostic Method Claims in the Wake of Mayo v. Prometheus," The Life Sciences Report, Spring 2013
- Co-author with A.N. Meyer, K.A. Drafahl, J.E. Gilda, L.H Gallo, M. Haas, L.M. Brill, and D.J Donoghue, "Tyrosine phosphorylation allows integration of multiple signaling inputs by IKKβ," PLoS One, 2013
- Co-author with L. Boeckmann, Y. Takahashi, W.C. Au, P.K. Mishra, J.S. Choy, A.R. Dawson, M.Y. Szeto, T.J. Waybright, C.D. Heger, P.K Goldsmith, T.D. Veenstra, R.E. Baker RE, and M.A. Basrai, "Phosphorylation of centromeric histone H3 variant regulates chromosome segregation in Saccharomyces cerevisiae," Molecular Biology of the Cell, 2013
- Co-author with J.M. Fleming, E. Ginsburg, C.D. Heger, L. Cheston, J. Rodriguez-Canales, B.K. Vonderhaar, and P.K. Goldsmith, "Characterization of △7/11, a functional prolactin-binding protein," Journal of Molecular Endocrinology, 2012
- Co-author with K.A. Drafahl, A.N. Meyer, and D.J. Donoghue, "The Receptor Tyrosine Kinase FGFR4 Regulates NF-kappaB Signaling," PLoS One, 2010
- Co-author with R.F. Gastwirt and D.J. Donoghue, "The Atypical CDK Activator Spy1 Regulates the Intrinsic DNA Damage Response and Is Dependent upon p53 to Inhibit Apoptosis," Cell Cycle, 2009
- Co-author with K.A. Drafahl and D.J. Donoghue, Signaling from FGF Receptors in Development and Disease, Humana Press, 2008
- Co-author with A.N. Meyer and D.J. Donoghue, "NDGA Inhibits an FGFR3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells," Cancer Research, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Regulation of the Cell Cycle," Wiley Encyclopedia of Chemical Biology, John Wiley & Sons, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Speedy/RINGO Regulation of CDKs in Cell Cycle, Checkpoint Activation and Apoptosis," Cell Cycle, 2007
- Co-author with R.F. Gastwirt, A.N. Meyer, L.A. Porter, and D.J. Donoghue, "Spy1 Enhances Phosphorylation and Degradation of the Cell Cycle Inhibitor," Cell Cycle, 2007
- Co-author with R.F. Gastwirt RF, D.A. Slavin, and D.J. Donoghue, "Spy1 Expression Prevents Normal Cellular Responses to DNA Damage: Inhibition of Apoptosis and Checkpoint Activation," Journal of Biology and Chemistry, 2006
- Co-author with D.T. Yeung, D. Josse, J.D. Nicholson, B.J. Bahnson, D.E. Lenz, and D.M. Cerasoli, "Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model," Biochimica et Biophysica Acta, 2004
Insights
Select Publications
- Co-author with D. Hoffmeister, V. Norviel, P. Girinath, and C. Andres, "FDA Developments in 2015 and What's to Come in 2016," Law360, January 11, 2016
- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," Generic Pharma 2.0, July 15, 2015
- Co-author with V. Norviel, E. Kepplinger, J. Chambers, and L. Lieto, "Strategies for Maximizing Patent Claim Scope and Patent Prosecution for Diagnostic Method Claims in the Wake of Mayo v. Prometheus," The Life Sciences Report, Spring 2013
- Co-author with A.N. Meyer, K.A. Drafahl, J.E. Gilda, L.H Gallo, M. Haas, L.M. Brill, and D.J Donoghue, "Tyrosine phosphorylation allows integration of multiple signaling inputs by IKKβ," PLoS One, 2013
- Co-author with L. Boeckmann, Y. Takahashi, W.C. Au, P.K. Mishra, J.S. Choy, A.R. Dawson, M.Y. Szeto, T.J. Waybright, C.D. Heger, P.K Goldsmith, T.D. Veenstra, R.E. Baker RE, and M.A. Basrai, "Phosphorylation of centromeric histone H3 variant regulates chromosome segregation in Saccharomyces cerevisiae," Molecular Biology of the Cell, 2013
- Co-author with J.M. Fleming, E. Ginsburg, C.D. Heger, L. Cheston, J. Rodriguez-Canales, B.K. Vonderhaar, and P.K. Goldsmith, "Characterization of △7/11, a functional prolactin-binding protein," Journal of Molecular Endocrinology, 2012
- Co-author with K.A. Drafahl, A.N. Meyer, and D.J. Donoghue, "The Receptor Tyrosine Kinase FGFR4 Regulates NF-kappaB Signaling," PLoS One, 2010
- Co-author with R.F. Gastwirt and D.J. Donoghue, "The Atypical CDK Activator Spy1 Regulates the Intrinsic DNA Damage Response and Is Dependent upon p53 to Inhibit Apoptosis," Cell Cycle, 2009
- Co-author with K.A. Drafahl and D.J. Donoghue, Signaling from FGF Receptors in Development and Disease, Humana Press, 2008
- Co-author with A.N. Meyer and D.J. Donoghue, "NDGA Inhibits an FGFR3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells," Cancer Research, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Regulation of the Cell Cycle," Wiley Encyclopedia of Chemical Biology, John Wiley & Sons, 2008
- Co-author with R.F. Gastwirt and D.J. Donoghue, "Speedy/RINGO Regulation of CDKs in Cell Cycle, Checkpoint Activation and Apoptosis," Cell Cycle, 2007
- Co-author with R.F. Gastwirt, A.N. Meyer, L.A. Porter, and D.J. Donoghue, "Spy1 Enhances Phosphorylation and Degradation of the Cell Cycle Inhibitor," Cell Cycle, 2007
- Co-author with R.F. Gastwirt RF, D.A. Slavin, and D.J. Donoghue, "Spy1 Expression Prevents Normal Cellular Responses to DNA Damage: Inhibition of Apoptosis and Checkpoint Activation," Journal of Biology and Chemistry, 2006
- Co-author with D.T. Yeung, D. Josse, J.D. Nicholson, B.J. Bahnson, D.E. Lenz, and D.M. Cerasoli, "Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model," Biochimica et Biophysica Acta, 2004
Recent Insights
Alerts
Federal Circuit Provides Guidance on What Claims Can Properly Serve As Obviousness-Type Double Patenting References
In a precedential decision issued on August 13, 2024, the U.S. Court of Appeals for the Federal Circuit held that a first-filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date.1
Learn More
Client Highlights
Firm Advises Marengo Therapeutics on Expansion of Research Partnership with Ipsen
On June 7, 2024, global biopharmaceutical company Ipsen and clinical-stage biotech company Marengo Therapeutics announced the expansion of their ongoing oncology research partnership to include TriSTAR, Marengo’s next-generation, precision T cell engager (TCE) technology. Wilson Sonsini Goodrich & Rosati advised Marengo Therapeutics on the transaction.
Traditional TCEs targeting “cold” tumors have limited efficacy due to poor T cell quality and exhaustion. Marengo’s proprietary first-in-class TriSTAR TCEs have the potential to overcome these limitations, redirecting a new and expanded pool of highly activated memory Vβ T cells to the tumor. The teams will focus on exploring potential in cold tumors, which typically fail to trigger a strong immune response when treated with TCEs.
Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.2 billion if all milestones are met, in addition to tiered sales royalty payments.
The Wilson Sonsini team advising Marengo Therapeutics on the transaction included Mark Bellomy, Chris McAndrew, Lauren Wardle, and Angel Wang.
Traditional TCEs targeting “cold” tumors have limited efficacy due to poor T cell quality and exhaustion. Marengo’s proprietary first-in-class TriSTAR TCEs have the potential to overcome these limitations, redirecting a new and expanded pool of highly activated memory Vβ T cells to the tumor. The teams will focus on exploring potential in cold tumors, which typically fail to trigger a strong immune response when treated with TCEs.
Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.2 billion if all milestones are met, in addition to tiered sales royalty payments.
The Wilson Sonsini team advising Marengo Therapeutics on the transaction included Mark Bellomy, Chris McAndrew, Lauren Wardle, and Angel Wang.
Learn More
Recent Events
Affiliated Programs
Yale Innovation Summit 2024
The Yale Innovation Summit, Sponsored by Wilson Sonsini Goodrich & Rosati, convenes the innovation and entrepreneurship community for two days of impactful conversations, purposeful networking, and Yale pitch competition across five tracks of programming. Celebrating its 10th year, the event has become one of the region’s biggest and most impactful innovation events, drawing investors, founders, and industry partners to Yale’s campus from around the world to create new connections and opportunities. Five tracks of programming will each feature keynotes, panel discussions, and pitch competitions in the arts, biotech, climate, health, and technology. This year’s event theme will focus on the event’s ten-year anniversary milestone, the transformational potential of AI, and the evolution of Yale and New Haven as a “next great innovation hub.”
Learn More
WSGR Events
Innovator’s Edge Series: The Life and Death of a Patent Family
A strong patent portfolio starts with thoughtfully-crafted patent strategies. Crafting a patent strategy begins with matching patent filing timelines to business timelines (including IND filings, marketing approval, expected market exclusivities, and fundraising). It also includes detailed planning for global patent protection in light of market opportunities and patent expiration dates. Finally, your patent strategy must also look at how to maximize patent term, for example through strategic use of accelerated filings.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.